| 14616-7 |
Nuclear Ab |
Titr |
Synv fld |
Pt |
SemiQn |
|
|
ACTIVE |
Nuclear Ab [Titer] in Synovial fluid |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
14616-7 |
|
|
|
|
Both |
|
|
|
0 |
ANA Titr Snv |
|
|
|
Y |
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); Joint aspirate; Joint fld; Joint flu; Joint fluid; NA; Nuc; Point in time; Random; Rheum; Rheumatology; Serology; SF; SmQn; Snv; Syn; Syn fl; Synov; Synovial fluid; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 14617-5 |
Observation |
Aper |
Pericard fld |
Pt |
Nom |
|
|
ACTIVE |
Appearance of Pericardial fluid |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
14617-5 |
|
|
|
|
Observation |
|
|
|
0 |
Appearance Pcar |
|
|
|
|
|
Appearance; Cardio; Cardiology; Heart Disease; Nominal; PCAR; Pericardial fluid; Point in time; Random; SPEC |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |
| 14618-3 |
Observation |
Aper |
Calculus |
Pt |
Nom |
|
|
ACTIVE |
Appearance of Stone |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
14618-3 |
|
|
|
|
Observation |
|
|
|
0 |
Appearance Stone |
|
|
|
|
|
Appearance; Calc; Calculi; Gastro; Gastroenterology; GI; Kidney; Nephrology; Nominal; Point in time; Random; Renal; SPEC; Stn; Stone; Stones |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |
| 14619-1 |
Observation |
Aper |
Plas |
Pt |
Nom |
|
|
ACTIVE |
Appearance of Plasma |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
14619-1 |
|
|
|
|
Observation |
|
|
|
0 |
Appearance Plas |
|
|
|
|
|
Appearance; Nominal; Pl; Plasma; Plsm; Point in time; Random; SPEC |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |
| 1462-1 |
Epinephrine^2H post 300 ug cloNIDine PO |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
EPINEPHrine [Mass/volume] in Plasma --2 hours post 300 ug cloNIDine PO |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
1462-1 |
|
|
|
|
Observation |
|
|
|
0 |
Epineph 2h p 300 ug CLN PO Plas-mCnc |
|
|
|
Y |
|
120 min; 120 minutes; 120min; 2 hours; 2h p 300 ug CLN PO; Adrenalin; Adrenaline; Adreneline; After; Catapres; CHEMISTRY.CHALLENGE TESTING; E; Epi; Epin; Epinep; Epineph; Epinphrine; Eppi; Level; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random |
2.73 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 14620-9 |
Observation |
Aper |
Plr fld |
Pt |
Nom |
|
|
ACTIVE |
Appearance of Pleural fluid |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
14620-9 |
|
|
|
|
Observation |
|
|
|
0 |
Appearance Plr |
|
|
|
|
|
Appearance; Nominal; Pleural; Pleural fluid; Point in time; Random; SPEC; thoracentesis fluid |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |
| 14621-7 |
Observation |
Aper |
Periton fld |
Pt |
Nom |
|
|
ACTIVE |
Appearance of Peritoneal fluid |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
14621-7 |
|
|
|
|
Observation |
|
|
|
0 |
Appearance Prt |
|
|
|
|
|
Appearance; Ascites; Ascitic fluid; Ascitis; Nominal; Peritoneal fluid; Point in time; Prt; Random; SPEC |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |
| 14622-5 |
Ascorbate |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Ascorbate [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
14622-5 |
|
|
|
|
Both |
|
|
|
0 |
Vit C SerPl-sCnc |
|
|
|
Y |
|
Ascorbic acid; c702; Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; UniversalLabOrders; Vit C; Vitamin C |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 14623-3 |
Barbital |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Barbital [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14623-3 |
|
|
|
|
Both |
|
|
|
0 |
Barbital SerPl Ql |
|
|
|
|
|
Addiction; Barbitone; Barbiturate; Diethylmalonylurea; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Megal; Neurinase; Ordinal; Pl; Plasma; Plsm; Pneumogeine-barbital; Point in time; PotentialForAbuse; PR; Provervon n; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Veraine buriat; Veronal; Vitanerton N Kerne |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 14624-1 |
Barbiturates |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
Barbiturates [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14624-1 |
|
|
|
|
Both |
|
|
|
0 |
Barbiturates Gast Ql |
|
|
|
|
|
Addiction; Barb; Barbiturate; Barbs; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GAST; Gastric contents; Gastric fluid; Illicit; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 14625-8 |
Basophils/Leukocytes |
NFr |
Bronchial |
Pt |
Qn |
Manual count |
|
ACTIVE |
Basophils/Leukocytes in Bronchial specimen by Manual count |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
14625-8 |
|
Manual count |
|
|
Observation |
|
|
|
0 |
Basophils NFr Bronch Manual |
|
|
|
Y |
|
Baso; Basophil; Basos; Bph; Bro; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Manl; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WBC; WBCs; White blood cell; White blood cells |
2.79 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 14626-6 |
Beta-2-Microglobulin |
SCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Beta-2-Microglobulin [Moles/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14626-6 |
|
|
|
|
Both |
|
|
|
0 |
B2 Microglob Ser-sCnc |
|
|
|
Y |
|
B; B2 Microglob; b2-M; Chemistry; Hematology; Heme; II; Level; Microglob; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 14627-4 |
Bicarbonate |
SCnc |
BldV |
Pt |
Qn |
|
|
ACTIVE |
Bicarbonate [Moles/volume] in Venous blood |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
14627-4 |
|
|
|
|
Both |
|
|
|
0 |
HCO3 BldV-sCnc |
|
|
|
Y |
|
BIC; bicar; Bicarb; Bld ven; Bld venous; Blood - venous; Blood ven; Blood venus; Chemistry; HCO3; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; Venous |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 14628-2 |
Bile acid |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Bile acid [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
14628-2 |
|
|
|
|
Both |
|
|
|
0 |
Bile Ac SerPl-sCnc |
|
|
|
Y |
|
Acd; Acids; Bile acid.total; Bile salt; Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; UniversalLabOrders |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
Updated System from Ser to Ser/Plas since this test can also be done on plasma. |
0 |
| 14629-0 |
Bilirubin.glucuronidated+Bilirubin.albumin bound |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Bilirubin.direct [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
14629-0 |
|
|
|
|
Both |
|
|
|
0 |
Bilirub Direct SerPl-sCnc |
|
|
|
Y |
|
Alb; Associated; Bc; Bili; Bili.delta; Bili-alb; Bilirub Conj; Bilirub Delta; Bilirub Direct; Bilirubin conjugated; Bilirubin direct; Bilirubin glucuronides; Bilirubins; Billirubin; bnd; Chemistry; DELB; Delta bilirubin; Deltab; Hematology; Heme; Hepatology; Level; Liver; Pl; Plasma; Plsm; Point in time; Protein.albumin; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; TBIL; TBIL-(Bu+Bc); TBIL-Bu |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 1463-9 |
Epinephrine^3H post 300 ug cloNIDine PO |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
EPINEPHrine [Mass/volume] in Plasma --3 hours post 300 ug cloNIDine PO |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
1463-9 |
|
|
|
|
Observation |
|
|
|
0 |
Epineph 3h p 300 ug CLN PO Plas-mCnc |
|
|
|
Y |
|
3h p 300 ug CLN PO; Adrenalin; Adrenaline; Adreneline; After; Catapres; CHEMISTRY.CHALLENGE TESTING; E; Epi; Epin; Epinep; Epineph; Epinphrine; Eppi; Level; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random |
2.73 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 14630-8 |
Bilirubin.non-glucuronidated |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Bilirubin.indirect [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
14630-8 |
|
|
|
|
Both |
|
|
|
0 |
Bilirub Indirect SerPl-sCnc |
|
|
|
Y |
|
Bili; Bilirub Indirect; Bilirubin indirect; Bilirubin non-conjugated; Bilirubin primary; Bilirubin unconjugated; Bilirubins; Billirubin; Bu; Chemistry; Hematology; Heme; Hepatology; Level; Liver; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; TBIL |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 14631-6 |
Bilirubin |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Bilirubin.total [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
14631-6 |
|
|
|
|
Both |
|
|
|
0 |
Bilirub SerPl-sCnc |
|
|
|
Y |
|
Bili; Bilirubins; Billirubin; Chemistry; Hematology; Heme; Hepatology; Level; Liver; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; TBIL |
2.73 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 14632-4 |
Buffy coat |
Imp |
Bld |
Pt |
Nom |
Microscopy.light |
|
DEPRECATED |
Deprecated Buffy coat |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
14632-4 |
|
Microscopy.light |
|
|
Observation |
|
|
|
0 |
Deprecated Buffy coat Bld Smear-Imp |
|
|
|
|
|
Blood; HEMATOLOGY/CELL COUNTS; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; LM; Micro; Micros; Microscopic; Nominal; Point in time; Random; WB; Whole blood |
2.36 |
1.0k |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 14633-2 |
C peptide |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
C peptide [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
14633-2 |
|
|
|
|
Both |
|
|
|
0 |
C peptide SerPl-sCnc |
|
|
|
Y |
|
Chemistry; Connecting peptide of insulin; Endocrine; Endocrinology; Level; Pept; Pl; Plasma; Plsm; Point in time; Pro-insulin c peptide; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
| 14634-0 |
C reactive protein |
Titr |
Ser/Plas |
Pt |
SemiQn |
|
|
ACTIVE |
C reactive protein [Titer] in Serum or Plasma |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
CHEM |
|
14634-0 |
|
|
|
|
Both |
|
|
|
0 |
CRP Titr SerPl |
|
|
|
Y |
|
Chemistry; CRP; Dilution factor; Dilution Factor (Titer); Pl; Plasma; Plsm; Point in time; PR; Prot; Random; Reac; React; SerP; SerPl; SerPlas; Serum; Serum or plasma; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 14635-7 |
Calcidiol |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
25-hydroxyvitamin D3 [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14635-7 |
|
|
|
|
Both |
|
|
|
0 |
25(OH)D3 SerPl-sCnc |
|
|
|
Y |
|
25(OH)D3; 25-hydroxycholecalciferol; 25-hydroxyvitamin D 3; 25-hydroxyvitamin D3; Calciderol; Calcifediol; Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Vitamin D 25 hydroxy |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 14636-5 |
Calcium |
PrThr |
Calculus |
Pt |
Ord |
|
|
ACTIVE |
Calcium [Presence] in Stone |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
14636-5 |
|
|
|
|
Both |
|
|
|
0 |
Calcium Stone Ql |
|
|
|
|
|
Ca; Cal; Calc; Calculi; Chemistry; Gastro; Gastroenterology; GI; Kidney; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; Stn; Stone; Stones |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 14637-3 |
Calcium |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Calcium [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/24 H |
|
|
|
|
|
|
CHEM |
|
14637-3 |
|
|
|
|
Both |
|
|
|
0 |
Calcium 24h Ur-sRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; Ca; Cal; Chemistry; Kidney; Nephrology; QNT; Quan; Quant; Quantitative; Renal; sRate; Substance Rate; UA; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/(24.h) |
|
|
|
0 |
| 14638-1 |
Calculus analysis |
Imp |
Calculus |
Pt |
Nom |
|
|
ACTIVE |
Calculus analysis [Interpretation] in Stone |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
14638-1 |
|
|
|
|
Observation |
|
|
|
0 |
Stone Analysis-Imp |
|
|
|
|
|
Calc; Calculi; Chemistry; Gastro; Gastroenterology; GI; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Kidney; Nephrology; Nominal; Point in time; Random; Renal; Stn; Stone; Stone Analysis; Stones |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
